Targeted drug delivery of Methotrexate in situ gels for the treatment of Rheumatoid Arthritis

Venkatesh, M. P.; Kumar, Tegginmat Pramod; Pai, Deeksha Ramananda

doi:10.1016/j.jsps.2020.10.003

Cited by 11 publications

(6 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…96 These systems were tested as delivery matrices for several compounds such as anticancer agents, [75][76][77]82,86,87 anti-inflammatory/anti-fungal/anti-bacterial/anti-microbial drugs, 79,81,91,100,101 cholesterol-lowering drugs, 198 antidiabetic drugs (insulin), 85 anticonvulsant agents 90,98 and vaccines. 92 Similar observations as in the previous studies were made, such as biocompatibility, 93 improved bioavailability of the compound, 88,94 controlled and prolonged release, [78][79][80][81][82][83][84][85][86][87] and control of tumour when anticancer agents were used. [75][76][77] In one of the studies, the gel loaded with vitamins was injected in a model animal suffering from skin burn, and wound healing was observed due to the antioxidant action of the vitamins.…”

Section: Poloxamer Basedsupporting

confidence: 67%

“…crosslinked poly(acrylic acid)) are well known for providing mucoadhesion. Similar to the previous studies, P407 or a combination of P407 and P188 78,79,84,85,[88][89][90][91] were mixed with poly(vinyl alcohol), 87 methylcellulose 80 and its derivatives, 75,[77][78][79]81,85,86,93,100,198 such as carboxymethylcellulose 79 and HPMC, 75,77,78,81,85,86,93,100,198 sodium alginate, 76,85 Carbopol®, 74,88,94,98 chitosan, 82,89,90,92,96,97,100,198 sodium poly(acrylate), 101 glycerin, 83 polycarbophil, 93,99 methoxy poly(ethylene glycol)-b-poly(D,L-lactic acid) (poly(MPEG-b-PDLLA)) …”

Section: Poloxamer Basedmentioning

confidence: 99%

See 1 more Smart Citation

Pre‐clinical and clinical applications of thermoreversible hydrogels in biomedical engineering: a review

Constantinou

Georgiou

2021

Polymer International

View full text Add to dashboard Cite

Thermoreversible polymer hydrogels (TRGs) are physical aqueous networks triggered by temperature that find potential applications in tissue engineering (TE) and drug/gene delivery. When systems with lower critical solution temperature (LCST) behaviour are used, the aqueous solution of polymer is mixed with cells or drugs/genes, depending on the desired application, at room temperature and then injected in vivo to form a hydrogel. This in situ forming hydrogel acts as a matrix for tissue regeneration or controlled and targeted release of the compound. This review focuses on discussing the studies in which synthetic TRGs with LCST behaviour have been applied in vivo in model animals. These studies are categorised depending on the general structure of the polymer, as follows: (i) poloxamers (also known as Pluronics®), (ii) degradable polymers, (iii) poly(N-isopropylacrylamide), (iv) poly(organophosphazene) and (v) poly(2-ethyl-2-oxazoline). In general, when the system is optimised, TRGs provide sustained and topical release of the drugs, thus minimising the undesired side effects. When applied in the TE field, tissue formation was observed. Interestingly, two polymers have reached clinical trials, namely poloxamer 407 (P407, Pluronic® F127, often combined with P188, F68) and Regel® (the formulation of Regel® with the anticancer agent paclitaxel is known as Oncogel®), indicating the challenges that need to be overcome before successful application in clinics.

show abstract

Section: Poloxamer Basedsupporting

confidence: 67%

Section: Poloxamer Basedmentioning

confidence: 99%

Pre‐clinical and clinical applications of thermoreversible hydrogels in biomedical engineering: a review

Constantinou

Georgiou

2021

Polymer International

View full text Add to dashboard Cite

show abstract

“…Once the mean release kinetic behaviors were determined, the means and standard deviations of the individual release data for both gels were calculated, as reported in Table 12. The first-order model confirmed that the D release mechanism from the 0.5% (w/w) gel was diffusion, according to Fick's Law [33,51]. However, the Weibull model was a nonmechanistic equation.…”

Section: In Vitro Release Of Disulfiram From the Gelmentioning

confidence: 65%

“…Syringeability was determined by calculating the time needed for 5 g of the product to fall from a cannula with the application of a constant force of 9.688 N (applied weight of 987.6 g) [ 33 ].…”

Section: Methodsmentioning

confidence: 99%

Repurposing Disulfiram as an Antifungal Agent: Development of a New Disulfiram Vaginal Mucoadhesive Gel

Lajarin-Reinares,

Naveira-Souto,

Mallandrich

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Alternative formulations need to be developed to improve the efficacy of treatments administered via the vaginal route. Mucoadhesive gels with disulfiram, a molecule that was originally approved as an antialcoholism drug, offer an attractive alternative to treat vaginal candidiasis. The aim of the current study was to develop and optimize a mucoadhesive drug delivery system for the local administration of disulfiram. Such formulations were composed of polyethylene glycol and carrageenan to improve the mucoadhesive and mechanical properties and to prolong the residence time in the vaginal cavity. Microdilution susceptibility testing showed that these gels had antifungal activity against Candida albicans, Candida parapsilosis, and Nakaseomyces glabratus. The physicochemical properties of the gels were characterized, and the in vitro release and permeation profiles were investigated with vertical diffusion Franz cells. After quantification, it was determined that the amount of the drug retained in the pig vaginal epithelium was sufficient to treat candidiasis infection. Together, our findings suggest that mucoadhesive disulfiram gels have the potential to be an effective alternative treatment for vaginal candidiasis.

show abstract

“…Moreover, MTX-NLC based smart gel exhibited a significant reduction in rat joint swelling during 28 days [ 86 ]. In a recent study, MTX was formulated with hydroxypropyl methylcellulose K4M (HK4M), polycarbophil (PCL), and pluronic F-127 and this developed in-situ thermoresponsive and injectable gel (M4) exhibited 93.26 ± 2.39% release of MTX at 96 h. Additionally, the gel was biocompatible at the injection site and in vivo analyses on Wistar rats showed a considerable decrease in paw oedema during 28 days [ 87 ].…”

Section: Hydrogels For Methotrexate Deliverymentioning

confidence: 99%

New Horizons in Hydrogels for Methotrexate Delivery

Dehshahri

Kumar

Madamsetty

et al. 2020

Gels

View full text Add to dashboard Cite

Since its first clinical application, methotrexate (MTX) has been widely used for the treatment of human diseases. Despite great advantages, some properties such as poor absorption, short plasma half-life and unpredictable bioavailability have led researchers to seek novel delivery systems to improve its characteristics for parenteral and oral administration. Recently, great attention has been directed to hydrogels for the preparation of MTX formulations. This review describes the potential of hydrogels for the formulation of MTX to treat cancer, rheumatoid arthritis, psoriasis and central nervous system diseases. We will delineate the state-of-the-art and promising potential of hydrogels for systemic MTX delivery as well as transdermal delivery of the drug-using hydrogel-based formulations.

show abstract

Targeted drug delivery of Methotrexate in situ gels for the treatment of Rheumatoid Arthritis

Cited by 11 publications

References 35 publications

Pre‐clinical and clinical applications of thermoreversible hydrogels in biomedical engineering: a review

Pre‐clinical and clinical applications of thermoreversible hydrogels in biomedical engineering: a review

Repurposing Disulfiram as an Antifungal Agent: Development of a New Disulfiram Vaginal Mucoadhesive Gel

New Horizons in Hydrogels for Methotrexate Delivery

Contact Info

Product

Resources

About